Effect of Autologous Hematopoietic Stem Cell Transplantation on Recurrent Refractory B Cell NHL and Its Factors Influencing Prognosis / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1366-1371, 2018.
Article
em Zh
| WPRIM
| ID: wpr-689929
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To analyze the effect of autologous hematopoietic stem cell transplantation in the treatment of patients with recurrent refractory B cell non-Hodgkin's lymphoma (NHL) and the related factors affecting the prognosis.</p><p><b>METHODS</b>The clinical data of 47 cases of recurrent refractory B cell NHL treated in our hospital were retrospectively analyzed. Survival curves were drawn by Kaplan-Meier, and survival analyses were performed. Univariate and multivariate analyses were used to analyze the prognostic factors.</p><p><b>RESULTS</b>The complete remission rate was 51.06% before autologous hematopoietic stem cell transplantation, but it increased to 65.96% after transplantation. The median survival time was 21 months, the 3 years progression-free survival rate was 40.43%, and the 3 years overall survival rate was 48.94%. The results of unvariate analysis showed that no using the rituximab in the first treatment and incomplete remission shown by PET/CT before transplantation all were the risk factors (P<0.05) affecting the prognosis. By multifactor analysis, it was found that the incomplete remission shown by PET/CT before transplantation was a risk factor for the prognosis(P<0.05).</p><p><b>CONCLUSION</b>The application of autologous hematopoietic stem cell transplantation for patients with relapsed and refractory B cell NHL can improve the clinical efficacy, and the incomplete remission shown by PET/CT before transplantation is more adverse to the patients' prognosis.</p>
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2018
Tipo de documento:
Article